Baseline characteristics | |
Gleason score, n (%) | |
≤7 | 1 (7) |
8 | 6 (43) |
9 | 6 (43) |
10 | 1 (7) |
Prior local treatment, n (%) | 3 (21) |
Radical prostatectomy, n | 1 |
Radical radiation therapy, n | 2 |
Patient characteristics at initiation of enzalutamide | |
Median age, years (range) | 78 (50–88) |
Median time from CRPC to initiation of enzalutamide, mo (range) | 5.1 (1.3–75.4) |
ECOG PS, n (%) | |
0 | 5 (36) |
1 | 6 (43) |
2 | 3 (21) |
≥3 | 0 |
Number of previous vintage hormone manipulations, median (range) | 3 (2–7) |
Metastatic site, n (%) | |
Bone | 13 (100) |
EOD1 | 1 (7) |
EOD2 | 7 (50) |
EOD3 | 6 (43) |
EOD4 | 0 |
Lymph node | 6 (43) |
Lung | 1 (7) |
Liver | 1 (7) |
PSA (ng/ml), median (range) | 89.9 (22.4–445.6) |
Hemoglobin (g/l), median (range) | 11.4 (9.7–14.0) |
LDH (U/l), median (range) | 254 (173–2028) |
ALP (U/l), median (range) | 205 (99–1303) |
Patient characteristics at time of initiation of abiraterone acetate | |
Median time from enzalutamide discontinuation to initiation of abiraterone acetate, day (range) | 1 (1–69) |
ECOG PS, n (%) | |
0 | 3 (21) |
1 | 5 (36) |
2 | 6 (43) |
≥3 | 0 |
PSA (ng/ml), median (range) | 38.0 (8.6–572.1) |
Hemoglobin (g/l), median (range) | 11.8 (9.2–14.0) |
LDH (U/l), median (range) | 202 (143–960) |
ALP (U/l), median (range) | 316 (117–717) |